Humana knew Q3 2026 was going to hurt. The question this morning is whether it hurt in the right way.
The Louisville insurer released third-quarter results at 6:00 a.m. ET today, and investors already knew the headline: management guided on July 29 to an adjusted loss of roughly $1.00 per share and an Insurance segment benefit ratio slightly above 94%. The loss was never a surprise. It was disclosed, pre-explained, and priced into the guidance Humana affirmed all year.
What actually matters this morning is whether the benefit ratio came in near that 94%-plus guide, and what management says about Q4 trajectory and the full-year floor of at least $9.00 in adjusted EPS.
The Repair Job in Numbers
To understand why the benefit ratio dominates everything else, consider the arc. Humana ran an 89.4% Insurance segment benefit ratio in Q1 2026 and 91.2% in Q2. The Q3 guidance of slightly above 94% reflects deliberate seasonal math: the company loads its sicker, higher-cost population into the back half of the year, and Stars rating headwinds for Bonus Year 2026 made that compression worse. The full-year Insurance segment benefit ratio guidance of 92.75%, plus or minus 25 basis points, still requires Q4 to come in meaningfully below Q3 to close the gap.
That math is only possible if the member exits are doing what Humana promised. At the Q2 earnings call, CFO Celeste Mellet told analysts the company’s 2027 plan exits would affect approximately 600,000 Medicare Advantage members, targeting plans rated 3.5 stars or below. Those exits represent roughly 8% of Humana’s 7.2 million MA members. The stated goal is a sustainable pretax Medicare Advantage margin of at least 3% by 2028.
Shedding unprofitable members should reduce the medical cost per remaining member. The question is whether the Q3 numbers confirm that dynamic is building, or whether elevated utilization among retained members is offsetting the pruning.
The Context Around the Numbers
Humana is not reporting into a vacuum. CVS announced Wednesday it will split its health care services business (including Aetna and Caremark) from its retail pharmacy business by the first half of 2028, a move that comes about a decade after the $78 billion Aetna deal. Meanwhile, Democrats won control of both chambers of Congress in the November 3 midterm elections. Party leaders have said early priorities include restoring enhanced ACA premium subsidies that expired at the end of 2025 and reversing Medicaid funding cuts enacted in last year’s GOP reconciliation law. Neither change helps Humana directly in the near term, but both reshape the broader coverage landscape in which Humana competes.
Bull Case, Bear Case
The bull case is simple: a managed loss with a contained benefit ratio sets up a sharp 2027 rebound. Analysts project full-year 2027 EPS of roughly $16, a 77% recovery from the depressed 2026 base, driven by benefit adjustments on the surviving member book, improved Stars scores in Bonus Year 2028, and CenterWell’s growing value-based footprint. If Q3 comes in at the guided level and Q4 guidance holds the full-year floor, that recovery story stays intact.
The bear case is that medical costs in the retained membership are running hotter than the exits can fix. Humana’s benefit ratio deteriorated 200 basis points year over year just in Q1 2026, before the exits had taken effect. If the Q3 ratio surprises above 94.5%, or if management shaves the full-year EPS floor, the 2027 recovery math gets substantially harder.
What to Watch Next
Three signals matter most from today’s release. First, whether the actual benefit ratio landed near the guided level of slightly above 94%, and by how much. Second, whether Humana reaffirms at least $9.00 in full-year 2026 adjusted EPS, which requires a sharp Q4 recovery. Third, any early commentary on 2027 membership retention from the 600,000 exit pool, since Humana has said it hopes to recapture a significant portion of those members into other plans.
The planned loss was never the news. The benefit ratio trajectory is.